首页 >>2020年03期
2019-nCoV:来自冠状病毒的新挑战
作者:田怀玉

摘要:

2019年岁末,在武汉暴发新型冠状病毒(2019-nCoV)引起的肺炎流行,给我国公共卫生和临床救治带来巨大挑战。2019-nCoV属于冠状病毒科β冠状病毒属,与严重急性呼吸综合征相关冠状病毒(SARS-CoV)和中东呼吸综合征相关冠状病毒(MERS-CoV)近缘,都会导致严重肺炎症状。该病毒经飞沫、接触等途径传播,潜伏期患者即具备传播性。目前数据表明:2019-nCoV比SARS-CoV毒力弱,但传播力强;造成其能够跨种传播的受体可能与SARS-CoV一致,都是血管紧张素转化酶Ⅱ(ACE2)。在此疾病暴发后,我国科技人员投入大量精力开展研究,快速开发出诊断试剂,初步确定了病原特性,并已筛选出可能抑制该病毒的临床药物,也正在加快研发疫苗。2019-nCoV的出现再次提醒我们建立系统的冠状病毒监测网络的重要性;也给突发疫情防控和应急科研提出了新挑战。

关键词:冠状病毒属;公共卫生;新型冠状病毒

Abstract:

The outbreak of pneumonia caused by the novel coronavirus (2019-nCoV) in Wuhan, Hubei province of China, at the end of 2019 shaped tremendous challenges to China′s public health and clinical treatment. The virus belongs to the β genus Coronavirus in the family Corornaviridae, and is closely related to SARS-CoV and MERS-CoV, causing severe symptoms of pneumonia. The virus is transmitted through droplets, close contact, and other means, and patients in the incubation period could potentially transmit the virus to other persons. According to current observations, 2019-nCoV is weaker than SARS in pathogenesis, but has stronger transmission competence; it′s mechanism of cross-species spread might be related with angiotensin-converting enzyme Ⅱ (ACE2), which is consistent with the receptor SARS-CoV. After the outbreak of this disease, Chinese scientists invested a lot of energy to carry out research by developing rapid diagnostic reagents, identifying the characters of the pathogen, screening out clinical drugs that may inhibit the virus, and are rapidly developing vaccines. The emergence of 2019-nCoV reminds us once again of the importance of establishing a systematic coronavirus surveillance network. It also poses new challenges to prevention and control of the emerging epidemic and rapidly responses on scientific research.

Key words: Coronavirus;Public health;2019-nCoV

发表日期:2020/3

引用本文:

图/表:

  • 10.3760/cma.j.issn.0253-9624.2020.03.002.F001:图1 2019新型冠状病毒(2019-nCoV)进化示意图;

    10.3760/cma.j.issn.0253-9624.2020.03.002.F001:图1 2019新型冠状病毒(2019-nCoV)进化示意图;

参考文献:

[1]CuiJ, LiF, ShiZL. Origin and evolution of pathogenic coronaviruses[J]. Nat Rev Microbiol, 2019,17(3):181-192. DOI: 10.1038/s41579-018-0118-9.
[2]HuangC, WangY, LiX, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[EB/OL].[2020-01-30].https://www.sciencedirect.com/sdfe/reader/pii/S0140673620301835/pdf.
[3]World Health Organization. Novel Coronavirus-China[EB/OL].[2020-01-30].https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/.
[4]ZhuN, ZhangD, WangW, et al. A novel coronavirus from patients with pneumonia in China, 2019[J]. N Engl J Med, 2020.DOI: 10.1056/NEJMoa2001017.
[5]XuX, ChenP, WangJ, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission[EB/OL].[2020-01-30].http://engine.scichina.com/publisher/scp/journal/SCLS/doi/10.1007/s11427-020-1637-5?slug=fulltext.
[6]ZhouP, YangX, WangX, et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin[EB/OL].[2020-01-30]. https://www.biorxiv.org/content/10.1101/2020.01.22.914952v1.full.pdf.
[7]JiW, WangW, ZhaoX, et al. Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross-species transmission from snake to human[EB/OL].[2020-01-30].https://www.citynews1130.com/wp-content/blogs.dir/sites/9/2020/01/23/Ji_et_al-2020-Journal_of_Medical_Virology.pdf.
[8]XuX, ChenP, WangJ,et al.Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission[EB/OL].[2020-01-30]. http://engine.scichina.com/doi/10.1007/s11427-020-1637-5.
[9]LiuT, HuJ, KangM, et al. Transmission dynamics of 2019 novel coronavirus (2019-nCoV) [EB/OL].[2020-01-30]. https://www.biorxiv.org/content/10.1101/2020.01.25.919787v1.full.pdf.
[10]ReadJM, BridgenJR, CummingsetDA, et al. Novel coronavirus 2019-nCoV: early estimation of epidemiological parameters and epidemic predictions[EB/OL].[2020-01-30]. https://www.medrxiv.org/content/10.1101/2020.01.23.20018549v1.full.pdf.
[11]ShenM, PengZ, XiaoY, et al. Modelling the epidemic trend of the 2019 novel coronavirus outbreak in China[EB/OL].[2020-01-30].https://www.biorxiv.org/content/10.1101/2020.01.23.916726v1.full.pdf.
[12]LiQ, GuanX, WuP, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia [J].N Engl J Med, 2020.[Epub ahead of print]. DOI: 10.1056/NEJMoa2001316.
[13]TsengCT, SbranaE, Iwata-YoshikawaN, et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus[J].PLoS One, 2012,7(4):e35421. DOI: 10.1371/journal.pone.0035421.
[14]PuF, GuoY, LiM, et al. Yogurt supplemented with probiotics can protect the healthy elderly from respiratory infections: a randomized controlled open-label trial[EB/OL].[2020-01-30].https://www.sci-hub.shop/10.2147/cia.s141518.

用户评论 0条

用户名: 密码: 登陆 注册
 
  • 9
  • 3
  •  4 : 页次:0/0页 共0条记录 5条/每页
    关于我们 | 专家风采 | 会员注册 | 继续教育
    地 址:北京市西城区东河沿街69号正弘大厦511室 邮 编:100052
    电话:010-51322302
    版权所有 中华医学会及中华预防医学杂志编辑部
    京ICP备 07035254 号